AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Graphpad prism 8 number at risk12/27/2022 ![]() ![]() However, women who receive HT are generally healthier, more educated, and more socioeconomically advantaged relative to non‐users, which could influence outcomes in observational studies.Ĭontinued controversy regarding benefits and risks of HT in clinical studies may be due to a lack of precision medicine in HT, as multiple factors can influence its efficacy and safety. HT prescriptions were based on a clinician's counsel, based on menopausal symptoms during the menopausal transition and on best practice for dose, type, and duration based on the individual's comorbidities and could be changed based on individual response profile. ![]() In contrast to clinical trials, multiple observational studies have indicated a protective association between HT and reduced risk of NDDs.ĭata from observational studies were based on prescription records regarding HT use. Thus, the impact of hormone therapy intervention during which menopausal symptoms occurred, for which hormone therapy was developed, was not evaluated. These clinical trials were conducted in postmenopausal women with no menopausal symptoms and who had aged passed the “critical window” for efficacy of hormone therapy to impact estrogenic action in brain.īy design, participants were uniformly treated with one HT formulation, dose, and duration of therapy. ![]() Results from ancillary studies of randomized clinical trials including the Women's Health Initiative Memory Study (WHIMS), Kronos Early Estrogen Prevention Cognitive and Affective Ancillary Study (KEEPS‐cog), and Early versus Late Intervention Trial with Estradiol‐Cognitive Endpoints (ELITE‐cog) indicated no beneficial or harmful effect of HT on cognitive function. Findings from clinical studies have not been consistent due to different characteristics of study participants and methodological approaches for study analyses,Īlthough preclinical studies have more clearly indicated the potential of estrogen therapy to protect against NDDs. Which may be associated with hormonal changes during and after menopause.įor decades, the association between menopausal hormone therapy (HT) and the incidence of NDDs has been debated. Women are at a greater lifetime risk for Alzheimer's disease (AD) relative to men, Neurodegenerative diseases (NDDs) associated with aging are a major public health concern, as the magnitude and proportion of populations aged 65 years and older continue to increase. ![]()
0 Comments
Read More
Leave a Reply. |